Novartis Company PDF

7/30/2019 Novartis Company PDF

1/14

| SEO Presentation | 4 January 20111

Our focus is on patients

Our purpose is to care and cure.We provide medicines to treat and prevent diseases,

ease suffering and improve quality of life.


2/14


Novartis is a world-leading healthcare company

Leading market position

One of 20 largest companies by market capitalization

Among most respected companies globally

2009 USD billion

Net sales: 44.3

Net income: 8.5

R&D investment: 7.5

Canada and LATAM

US

EuropeAsia/Africa/Australasia

Sales by region 2009Key figures


3/14

3

The healthcare environment is undergoingunprecedented change

Agingpopulation

Unhealthylifestyles

Emergingmarkets

Advances inscience andtechnology

Poor nutritional habits and sedentary

lifestyles are increasing the prevalenceof chronic diseases

Economic growth of emerging countriesis providing healthcare access

New technological discoveries andtrends are enabling the development ofinnovative medicines while increasingthe cost of innovation

7KHZRUOGVSRSXODWLRQLVDJLQJ0RUHhealthcare treatments are needed, alsoprompting payors to aggressivelymanage costs



4/14

4

Environment Patient needs Novartis portfolio

Pharmaceuticals

Vaccines and

Diagnostics

Sandoz(Generics)

Consumer Health(OTC, Animal Health

and CIBA Vision)

Full rangeof healthcareoptions

Innovativemedicines

Prevention

Affordableoptions

Self-care

We believe our portfolio best meets the varied andoften complex needs of patients and societies



5/14

5

We have a broad healthcare portfolio

PharmaceuticalsInnovative patent-protectedmedicines

Vaccines andDiagnostics

Vaccines and diagnostic toolsto protect against life-threatening diseases

SandozAffordable, high-quality genericmedicines and biosimilars

ConsumerHealth

Strong, trustworthy brands forknowledgeable consumersOTC (Over-the-Counter) Animal HealthCIBA Vision

2009 net sales by division

Sandoz

Pharmaceuticals

V&D

ConsumerHealth



6/14

6

Strengthening the healthcare portfolio with Alcon

Eye care segment is highly attractive Large and profitable segment (USD 25 bn, 20%-30% EBIT)

Dynamic growth (aging population, emerging markets, innovation)

Alcon is the world leader in this attractive segment

Clear No. 1 in surgical and pharmaceutical eye care markets Strong performance track with double digit top- and bottom-line

Alcon stake expected to strengthen Novartis growth portfolio

Access to one of the fastest growing healthcare areas

Strengthen non-branded Rx businesses and expand in specialty areas Synergies of portfolios (front vs. back-of-the-eye), manufacturing and

distribution

Diversify risk (fewer generics, more self-pay)



7/14

7

We seek to constantly innovate

Unrivaled pipeline with approximately 152 projects inclinical development

Most new US drug approvals in the industry since 2000

2QHRIWKHLQGXVWU\VELJJHVWLQYHVWRUVLQUHVHDUFK

More than 17% of annual group net salesreinvested in R&D in 2008

Innovation across the Novartis group

Focusing on unmet medical needs inspires us toconnect science with customer insights to developnew products and drive industry standards

http://creative.gettyimages.com/source/Search/88','28','1','http://creative.gettyimages.com/source/Search/66','6','1','SS18


8/14

8

Novartis A leading healthcare company

1996 1997 1999 2000 2001 2002 2003 2005 2006 2007 2008

March:Sandoz andCiba-Geigyannouncemerger plans

December:Formation ofNovartis

May:ADS listingon New YorkStockExchange

July:Novartisone of firstcompaniesto signUN GlobalCompact

May:Initial stakeacquired inRoche, laterincreasingto 33%

November:NITD opensinSingaporeto researchtropicaldiseases

May:Creationof NovartisInstitutes forBiomedicalResearch forpharma-ceuticalsresearch

August:Acquisitionof Lek, aSloveniangenericscompany

May:Unificationof allgenericsoperationsunderhistoricSandozbrand

June/July:Acquisitionof genericleadersHexal andEon Labs

August:Acquisitionof OTCbrands fromBristol-MeyersSquibb

April:Entry intohumanvaccinesthrough Chironacquisition

February:Opening ofNovartisVaccines Institutefor Global Health

April/July:Rights to acquiremajority stake inAlcon, a worldleader in eyecare, from Nestl,initial 25% stakepurchased in July

March:Spin-offof CibaSpecialtyChemicalsbusiness

December:Spin-off ofagribusinessto formSyngenta

February:Sale ofNutrition& Santbusiness

July:Sale of MedicalNutritionbusiness

September:Sale of Gerberbaby productsbusiness

Healthcare Other



9/14

9

Focused diversification in healthcare

20021996 2007

45%80% 100%

Healthcare Other

2009 targeted acquisitions and strategic investments:

EBEWE Pharmaspecialty generics

85% stake inZhejiang Tianyuan



10/14

10

Strong performance in all business areas

Sales by division 2009 Sales by region 2009Consumer

Health

Sandoz

Pharmaceuticals

Company overviewEmployees: 99 834

Countries: 140

Headquarters: Basel, Switzerland

2009 USD billion

Net sales: 44.3

Net income: 8.5

R&D investment: 7.5

Key facts

V&D

Canada and LATAM

US

EuropeAsia/Africa/Australasia



11/14

11

Gilenya



12/14

12

Operating responsibly is integral to our success

Corporate citizenship at Novartis rests on four pillars: patients,people and communities, the environment and business conduct

Environment

Risk prevention& management

Resourcemanagement

Patients

Access

Research

Clinical trials Dialogue

People andcommunities Diversity &

inclusion

Living wage

Health & safety

Communityinvolvement

Emergency aid

Businessconduct Integrity &

Compliance

Marketingpractices

Third-partymanagement

Integrity Line



13/14

13

Access-to-medicine programs in 2009 we supported 79.5 million patients

1Novartis Institute for Tropical Diseases;2Novartis Vaccines Institute for Global Health;3Based on approximate market value

2009

Programs andresearch valuedat USD 1.5 bn3

Contributed 3%

of net sales

Coartem subsidized84 million treatments shipped cumulativelydelivered 300 million treatments, helping to saveabout 750,000 lives

Leprosy medication free of charge>4.5 million patients cured since 2000

Tuberculosis medicine donations500,000 treatments committed, 50% delivered

Glivec patient assistanceFree to >37,000 patients in about 80 countries

NITD1 in SingaporeFocus on tuberculosis, dengue fever and malaria

NVGH2 in Siena, ItalyVaccines research institute for neglected diseases



14/14

14

We make a difference for patients

0\GLVHDVHDIIHFWVVRIHZpeople, no one cared toUHVHDUFKDWUHDWPHQWXQWLOQRZ

Siobhan Walshrare disease patient

7KHPRUH,WDNHFDUHRImyself, the less othersZLOOKDYHWR

Odell Hallavid exerciser

,IWKHUHZDVDYDFFLQHIRUmeningitis B, my daughterZRXOGVWLOOEHDOLYHWRGD\

Robert Lelandfather

:KHQ\RXWDNHDVPDQ\medicines as I need,FRVWLVDQLVVXH

Luz Martinezsenior citizen

Novartis is deploying our understanding of

biological mechanisms toward a range ofmajor diseases while also offering hope topatients with rare illnesses who couldbenefit from these discoveries.

Novartis empowers patients and consumersby providing a wide range of readily-availablehealthcare products.

Novartis is a leader in providing vaccines that

protect against life-threatening viral andbacterial diseases, with a priority researchfocus on developing new vaccines to preventmeningococcal infections.

Novartis offers patients high-quality,affordable generic medicines to reducefinancial burden.


Documents

Novartis Company PDF